Onyx Pharmaceuticals, Inc. : Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
03/14/2013| 07:05am US/Eastern
Recommend:
LONDON, March 14, 2013 /PRNewswire/ --
The expiration of patents on several blockbuster drugs has been one of the major
trends in the biotechnology sector in the last few years. As major pharmaceutical
companies face increasing generic competition following patent expirations, they are
likely to see a negative impact on their top-line. Big pharmaceutical companies have been
looking to boost their product pipeline to offset the impact of the patent cliff. Another
trend that could emerge as a result of this development is acquisitions. Big pharma
companies may look to acquire smaller biotechnology companies that are developing
potential blockbuster drugs. Companies such as Sequenom Inc. (NASDAQ: SQNM), Peregrine
Pharmaceuticals (NASDAQ: PPHM), Onyx Pharmaceuticals Inc. (NASDAQ: ONXX), and Inovio
Pharmaceuticals Inc. (NYSEAMEX: INO) could be among the ideal takeover targets for major
pharmaceutical companies. On Wednesday, biotech stocks ended on a mixed note even as the
Dow Jones posted its ninth successive higher finish. StockCall has posted free technical
research reports on SQNM, PPHM, ONXX, and INO and these can be accessed by signing up at
http://www.stockcall.com/analysis
Sequenom Inc. shares posted modest gains on Wednesday, closing 0.45% higher at $4.48.
The stock touched an intra-day high of $4.51, and has gained nearly 4% this week. Despite
the recent gains, the biotech company's shares have fallen nearly 5% this year, even as
the broad market has posted significant gains for the year. The company's shares have been
struggling to break through $4.60 resistance level. The stock has just moved above its
50-day moving average, though, which is a bullish signal. The stock's MACD has also
crossed above the zero-line, which further confirms the positive trend. Download the free
report on SQNM upon registration at
http://www.StockCall.com/SQNM031413.pdf
Peregrine Pharmaceuticals shares saw a sharp decline in Wednesday's session as
investors digested the company's quarterly results. The stock closed 6.33% lower at $1.48
after touching an intra-day low of $1.43. The company's shares are down more than 10% for
the week. Despite the recent losses, the stock has outperformed the broad market this
year. Year-to-date, Peregrine's shares have gained over 12% as compared to a jump of 9%
for the S&P 500. The MACD chart for PPHM is giving bearish signal at the moment. The stock
is also trading below its 50-day moving average. PPHM technical report can be accessed for
free by signing up at
http://www.StockCall.com/PPHM031413.pdf
Although Onyx Pharmaceuticals Inc. shares edged lower in trading yesterday, losses
were limited. The stock ended the day 0.61% lower at $87.29 after falling to an intra-day
low of $88.55. Onyx's shares are up nearly 2% for the week, despite Wednesday's pullback.
The stock has had an excellent run so far this year, gaining more than 15%. The company's
shares have seen a series of highs over the last few trading sessions, which is a bullish
signal. The upbeat trend is confirmed by recent volume activity. The free report on ONXX
can be downloaded by signing up now at
http://www.StockCall.com/ONXX031413.pdf
Shares of Inovio Pharmaceuticals Inc. gained in the previous trading session, closing
0.43% higher at $0.540 on above average volume of 2.99 million yesterday. Inovio's shares
had fallen sharply last week; however, the stock has bottomed out at around $0.525. Free
report on INO can be accessed by registering at
http://www.StockCall.com/INO031413.pdf
About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and
comprehensive research and opinions on stocks making the headlines. Sign up today to talk
to our financial analyst at
http://www.stockcall.com
SOURCE StockCall.com
Recommend :
